http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 30 Aug 2026 07:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Press+Releases/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396 http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html <p> Phase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in <i>The Journal of the American Medical Association</i> </p><p> <b>Not intended for UK Media</b> </p> <p> WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the http://www.streetinsider.com/Business+Wire/Bayer+Announces+Phase+III+REVEAL+Study+with+Investigational+PET+Radiotracer+Iodine+124+Evuzamitide+Presented+as+Late-Breaker+at+ESC+2026/26999684.html Sun, 30 Aug 2026 07:45:00 -0400 A.06822034 A.07197289 A.30142833 A.50216935 BAYN BAYN BAYRY BAYZF O.00003102 O.00258640 O.20026344 O.22039545 O.48341396